ADMA Biologics宣布与摩根大通加速1.25亿美元股票回购

2026-03-02 20:46

ADMA Biologics (ADMA) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association.
Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of $125 million and will initially receive approximately 6.4 million shares of its common stock on or about March 3, 2026. This will represent approximately 80% of the shares expected to be repurchased under the ASR, based on the closing price of ADMA’s common stock of $15.57 per share on February 27, 2026.
The ASR agreement was executed pursuant to the company’s existing share repurchase program, under which the company has up to $500 million authorized for repurchases.
Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. The company said that the management believes these actions enhance long-term stockholder value and reflect a disciplined and opportunistic approach to capital allocation.
ADMA +0.83% premarket to $15.7.
Source: Press Release

More on ADMA Biologics